Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

由 Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Batchuluun, Purev, Munkhzaya, Chogsom, Purevsuren, Genden, Dandii, Dorjiin, Hulan, Tsogkhuu, Oyungerel, Dandii, Kutsyna, Galyna A, Reid, Alan A, Borisova, Vika, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S
發表在 J Hepatocell Carcinoma (2017)